Recommendations for the prevention of infective endocarditis and prosthetic joint infection in high-risk patients undergoing invasive dental procedures
DOI:
https://doi.org/10.14748/6pjp7257Keywords:
infective endocarditis, prosthetic joint infection, antibiotics, antibiotic prophylaxis, dental proceduresAbstract
Infective endocarditis (IE) is a rare but severe condition resulting from bacteremia. It is caused by microorganisms that enter the bloodstream and reach the endocardium, one or more heart valves, or blood vessels in patients at high risk for its development. Prosthetic joint infection is a serious complication following knee or hip arthroplasty and is the major cause of its failure.
Following invasive medical and dental procedures, bacteremia can cause complications in high-risk patients. The goal of antibiotic prophylaxis (AP) is to limit or eliminate transient bacteremia resulting from invasive procedures.
This review aims to summarize and discuss the global recommendations of the cardiologic and orthopedic societies for antibiotic prophylaxis in invasive dental procedures concerning the growing risk of antimicrobial resistance and its severe effects on public health.
The data search was performed using the selected keywords in PubMed, Scopus, Web of Science, and Google Scholar databases. After careful study selection, 30 articles were included in this review.
The use of AP is only indicated in patients at high risk of developing IE who undergo invasive dental treatment. The drug of choice for AP in patients at risk is amoxicillin/clavulanic acid. In allergic-to-penicillin patients, cephalosporins (not used in patients reporting immediate allergic reactions), clarithromycin, azithromycin, and doxycycline can be used. Clindamycin is no longer recommended for the prophylaxis of IE. Routine use of antibiotics for dental procedures following total joint replacement is currently not recommended.
References
[1] Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. Infective endocarditis. Nat Rev Dis Primers. 2016 Sep 1;2:16059. doi: 10.1038/nrdp.2016.59.
[2] Iaccarino A, Barbone A, Basciu A, Cuko E, Droandi G, Galbiati D, et al. Surgical Challenges in Infective Endocarditis: State of the Art. J Clin Med. 2023 Sep 11;12(18):5891. doi: 10.3390/jcm12185891.
[3] Daly CG. Antibiotic prophylaxis for dental procedures. Aust Prescr. 2017 Oct;40(5):184-8. doi: 10.18773/austprescr.2017.054.
[4] Janszky I, Gémes K, Ahnve S, Asgeirsson H, Möller J. Invasive Procedures Associated With the Development of Infective Endocarditis. J Am Coll Cardiol. 2018 Jun 19;71(24):2744-52. doi: 10.1016/j.jacc.2018.03.532.
[5] American Academy of Pediatric Dentistry. Antibiotic prophylaxis for dental patients at risk for infection. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2024:538-44.
[6] Thoresen T, Jordal S, Lie SA, Wünsche F, Jacobsen MR, Lund B. Infective endocarditis: association between origin of causing bacteria and findings during oral infection screening. BMC Oral Health. 2022 Nov 15;22(1):491. doi: 10.1186/s12903-022-02509-3.
[7] Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.
[8] Maharaj B, Coovadia Y, Vayej AC. An investigation of the frequency of bacteraemia following dental extraction, tooth brushing and chewing. Cardiovasc J Afr. 2012 Jul;23(6):340-4. doi: 10.5830/CVJA-2012-016.
[9] Gerova-Vatsova T. Treatment approach to generalized severe periodontitis with the potential for additional tooth loss: a case report. Cureus. 2024;16(11), e73336. doi:10.7759/cureus.73336
[10] Nelson SB, Pinkney JA, Chen AF, Tande AJ. Periprosthetic Joint Infection: Current Clinical Challenges. Clin Infect Dis. 2023 Oct 5;77(7):e34-e45. doi: 10.1093/cid/ciad360.
[11] Mikziński P, Kraus K, Widelski J, Paluch E. Modern Microbiological Methods to Detect Biofilm Formation in Orthopedy and Suggestions for Antibiotic Therapy, with Particular Emphasis on Prosthetic Joint Infection (PJI). Microorganisms. 2024 Jun 14;12(6):1198. doi: 10.3390/microorganisms12061198.
[12] Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. doi: 10.1093/eurheartj/ehad193.
[13] Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ. 2008 Apr 5;336(7647):770-1. doi: 10.1136/bmj.39510.423148.AD.
[14] Thornhill MH, Dayer M, Lockhart PB, McGurk M, Shanson D, Prendergast B, et al. A change in the NICE guidelines on antibiotic prophylaxis. Br Dent J. 2016 Aug 12;221(3):112-4. doi: 10.1038/sj.bdj.2016.554.
[15] Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185. doi: 10.1016/j.jacc.2014.02.536.
[16] Litvinov E, Litvinov A. Impact of clindamycin on the oral-gut axis: gastrointestinal side effects and Clostridium difficile infection in 45 patients. Cureus. 2024 Dec 9;16(12). 10.7759/cureus.75381
[17] Wang J, Zou D, Li Y, Liu P, Guo C. Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system. Front Pharmacol. 2023 Apr 13;14:1161728. doi: 10.3389/fphar.2023.1161728.
[18] Baddour LM, Shafiyi A, Lahr BD, Anavekar NS, Steckelberg JM, Wilson WR, et al. A Contemporary Population-Based Profile of Infective Endocarditis Using the Expanded Rochester Epidemiology Project. Mayo Clin Proc. 2021 Jun;96(6):1438-1445. doi: 10.1016/j.mayocp.2020.08.044.
[19] Gerova-Vatsova T. Investigating the efficacy of regenerative therapy with autogenous platelet-rich plasma in vertical bone defects. Cureus. 2024; 16(10), e72686. doi:10.7759/cureus.72686.
[20] Gerova-Vatsova T. Initial clinical and cone-beam computed tomography (CBCT) outcomes of enamel matrix derivative-based regenerative therapy in vertical bone defects. Cureus. 2024;16(10):e72180. doi:10.7759/cureus.72180.
[21] Gerova-Vatsova T. The efficacy of collagen barrier membranes in regenerating vertical bone defects: a clinical and cone beam computed tomography (CBCT) assessment. Cureus. 2024;16(10):e72550. doi:10.7759/cureus.72550
[22] Karpiński TM, Szkaradkiewicz AK. Chlorhexidine--pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1321-6.
[23] Cieplik F, Jakubovics NS, Buchalla W, Maisch T, Hellwig E, Al-Ahmad A. Resistance Toward Chlorhexidine in Oral Bacteria - Is There Cause for Concern? Front Microbiol. 2019 Mar 22;10:587. doi: 10.3389/fmicb.2019.00587.
[24] Gavazova-Hristozova G. Clinical and microbiological studies on the effect of the application of 0.2% chlorhexidine digluconate on postextraction bacteremia, halitosis, and the color of teeth. Dissertation. Plovdiv;2022. (in Bulgarian).
[25] Diogenes CM, Cha BY. AAE Guidance on antibiotic prophylaxis for patients at risk of systemic disease. American Association of Endodontists. 2017:1-6.
[26] Sollecito TP, Abt E, Lockhart PB, Truelove E, Paumier TM, Tracy SL, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015 Jan;146(1):11-16.e8. doi: 10.1016/j.adaj.2014.11.012.
[27] Scott JF, Morgan D, Avent M, Graves S, Goss AN. Patients with artificial joints: do they need antibiotic cover for dental treatment? Aust Dent J. 2005 Dec;50(4 Suppl 2):S45-53. doi: 10.1111/j.1834-7819.2005.tb00386.x.
[28] Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother. 2015 Aug;70(8):2382-8. doi: 10.1093/jac/dkv115.
[29] New CDA position statement on dental patients with orthopedic implants. J Can Dent Assoc. 2013;79:d126.
[30] Hellyer P. Joint replacement and antibiotic prophylaxis. Br Dent J. 2023 Mar 1;234(5):326-.
[31] New Zealand Dental Association. NZDA code of practice: Antibiotic prophylaxis for dental treatment of patients with prosthetic joint replacements (adopted March 2003). N Z Dent J. 2003 Sep;99(3):63-4.
[32] Rademacher WMH, Walenkamp GHIM, Moojen DJF, Hendriks JGE, Goedendorp TA, Rozema FR. Antibiotic prophylaxis is not indicated prior to dental procedures for prevention of periprosthetic joint infections. Acta Orthop. 2017 Oct;88(5):568-74. doi: 10.1080/17453674.2017.1340041.
[33] Overbye KM, Barrett JF. Antibiotics: where did we go wrong?. Drug discovery today. 2005 Jan 1;10(1):45-52.
[34] Spellberg B. The future of antibiotics. Critical care. 2014 Jun;18:1-7.
[35] Feller E. Why do doctors overprescribe antibiotics. RI Med J. 2019 Feb 1;102(1):9-10.
[36] Amin ME, Amine A, Newegy MS. Perspectives of pharmacy staff on dispensing subtherapeutic doses of antibiotics: a theory informed qualitative study. Int J Clin Pharm. 2017 Oct;39:1110-8.
